Targeting LAG-3/Gal-3 therapy overcomes immunosuppression and enhances anti-tumor response in endometrial cancer (24), multiple myeloma (25), and vulvar squamous neoplasia (26). This evidence concerns the gene LAG3 and neoplasm.